IGFBP2 and central nervous system cancer: Accordingly, the combination of plasmatic IGFBP2 and anti-IGFBP2 antibodies levels has already been tested in lung, glioma, and colorectal cancer patients and found to improve not only diagnostic efficacy of the test, but also its prognostic power.